Forecast
Healthy people use elective implants that materially enhance cognition by 2126.
Last revised Sep 11, 2026.
Current estimate
probability this has happened by each date
At least ten thousand people with no qualifying medical indication, in at least one jurisdiction, carry an implant that raises memory, reasoning, or learning above each recipient's own pre-implant baseline, sustained for at least twelve months and measured on a validated instrument.
Resolution criteria
- 2126
- At least ten thousand people with no qualifying medical indication, in at least one jurisdiction, carry an implant that raises memory, reasoning, or learning above each recipient's own pre-implant baseline, sustained for at least twelve months and measured on a validated instrument.
Probability history
| Revised | State | p(2035) | p(2050) | p(2100) |
|---|---|---|---|---|
hf-forecast-0021 | researched | — | — | — |
hf-forecast-0004 | initial prior | — | — | — |
Strongest evidence for
- The effects are real where they have been measured, including a 35 to 37 percent memory improvement from a model-driven hippocampal prosthesis (hf-evidence-0029).
- Neuralink and Synchron explicitly name enhancement as a medium to long-term objective, so intent exists among the best-funded developers (hf-evidence-0033).
- Elective surgery on healthy people at scale has strong precedent: cosmetic procedures are routine, carry real risk, and treat no disease, which shows the adoption barrier is not categorical.
- Every obstacle found is a maturity curve rather than a wall. Durability, bandwidth, surgical risk and regulatory category have all moved substantially for other technologies inside a century.
- The seed's own day-one takeaway predicted restoration before enhancement, so finding exactly that is confirmation of the sequence rather than evidence the sequence stops.
Strongest evidence against
- Every human memory-stimulation result located is in a clinical population with clinically placed electrodes: 25 epilepsy patients for the 15 percent recall effect, 8 stimulated epilepsy patients for the 35 to 37 percent prosthesis effect (hf-evidence-0028, hf-evidence-0029).
- The strongest closed-loop result fires stimulation precisely when a classifier predicts POOR encoding, making it restorative by construction rather than enhancing (hf-evidence-0028).
- Hardware does not last a lifetime: mean electrode yield 35.6 percent declining to 34, three of fourteen arrays never producing useful signal, and a longest follow-up of 7.6 years (hf-evidence-0030).
- A healthy recipient would accept roughly 2.8 percent haemorrhage and 3.4 to 3.8 percent intracranial complication risk against no deficit at all (hf-evidence-0031).
- No regulator has a category for a device indicated to enhance a person with no medical condition (hf-evidence-0032).
- Current invasive interfaces sample about 1,000 neurons of roughly 16 billion cortical neurons (hf-evidence-0033).
Present uncertainties
- Whether a high-bandwidth interface eventually offers something external tools categorically cannot, such as direct low-latency access to computation, which would defeat the structural argument entirely.
Next discriminating observation
The first regulatory submission for an enhancement indication in people with no medical condition; and the first replicated demonstration of memory improvement above baseline in healthy volunteers rather than in patients.
Sources
- Closed-loop stimulation of temporal cortex rescues functional networks and improves memory
In 25 patients undergoing intracranial monitoring for drug-resistant epilepsy, lateral temporal cortex stimulation triggered when a classifier predicted poor encoding raised the relative probability of item recall by 15 percent, with an odds ratio of 1.18.
Limit: A clinical population with clinically placed electrodes, not healthy volunteers, and a single-session task effect rather than sustained enhancement. The paper does NOT stratify results by baseline memory ability, so it says nothing about whether the effect exists in people whose memory is already good.
Fetched and confirmed directly by the master agent.
- Developing a hippocampal neural prosthetic to facilitate human memory encoding and recall
Closed-loop stimulation of CA1 derived from each subject's own CA3 firing patterns improved delayed match-to-sample memory performance by roughly 35 to 37 percent, in 8 stimulated subjects drawn from 22 enrolled.
Limit: Eight stimulated subjects, all with medically refractory epilepsy undergoing clinically necessary electrode implantation, on a laboratory task rather than sustained real-world cognition. Nobody in this study was a healthy elective recipient.
Retrieved by a delegated source worker from a primary page and not independently re-fetched.
- Long-term performance of intracortical microelectrode arrays in 14 BrainGate clinical trial participants
Across 14 participants carrying 20 arrays, implant duration ranged from 296 to 2780 days with a mean of 1063. Arrays recorded usable spiking on an average of 35.6 percent of electrodes, declining from 41 percent in the first three months to 34 percent in the last. Three of fourteen arrays evaluated for decoding failed to consistently produce useful signal, and just over half maintained at least 20 percent yield across the first three years.
Limit: Severely paralysed trial participants selected for likely benefit, measuring restoration of motor communication rather than enhancement, and the longest follow-up is 7.6 years rather than decades. It does not show that durable materials are impossible, only that none is yet demonstrated.
Fetched and confirmed directly by the master agent.
- Complication rates for implanted deep brain stimulation hardware
Pooled surgical series report haemorrhage around 2.8 percent, ischaemic stroke 0.6 percent, seizures 1.1 percent, wound complications around 7.2 percent, intracranial complications of 3.4 to 3.8 percent, and hardware removal for infection or erosion of 3.8 to 4.3 percent per patient.
Limit: Rates come from therapeutic populations who are typically older and sicker than a hypothetical healthy elective recipient, so they likely overstate the risk a young healthy person would face, and surgical technique has a century to improve. Heterogeneity across the pooled series was high.
Retrieved by a delegated source worker from a primary page and not independently re-fetched.
- FDA regulatory overview, neurological devices
The regulatory framework is organised entirely around treating or diagnosing disease and conditions such as paralysis, tumours, aneurysm and stroke, with implanted stimulation devices in the highest risk class requiring premarket approval. No approval route is described for a device indicated to enhance function in a person with no medical condition.
Limit: One regulator's overview page rather than an exhaustive survey, and absence of a pathway today says little about a century in which regulators have repeatedly created categories for elective procedures.
Retrieved by a delegated source worker from a primary page and not independently re-fetched.
- Ethical considerations for the use of brain-computer interfaces for cognitive enhancement
Enhancement is not generally an immediate goal for developers, though Neuralink and Synchron explicitly name it as a medium to long-term objective. The authors put near-term enhancement applications at the level of controlling apps on a phone, and note that current invasive interfaces sample roughly 1,000 neurons out of about 16 billion cortical neurons, alongside incomplete understanding of distributed neurocognitive processes.
Limit: A review and ethical analysis rather than a measurement study. The neuron-count comparison is an order-of-magnitude framing, not a claim that enhancement requires addressing all of cortex.
Fetched and confirmed directly by the master agent.